RDInvesting Provides Investors with Free In-Depth Equity Reports on CNCE, LNDC, NBG and PIP


Follow this company

Companies Mentioned

NASDAQ:CNCE / NASDAQ:LNDC / NYSE:NBG / NYSE:PIP
03/11/2014 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous s stock reports and market updates.

Concert Pharmaceuticals Inc. (NASDAQ: CNCE) shares increased 1.01 percent to close at $15.03 a share Monday. The stock traded between $14.59 and $15.84 on volume of 333,252 shares traded. Analysts at UBS have recently initiated coverage on the company with a “buy” rating. Shares of Concert Pharmaceuticals have gained approximately 5.0 percent year-to-date.

Find out more about Concert Pharmaceuticals including full access to the free equity report at:       
www.RDInvesting.com/CNCE

Landec Corporation (NASDAQ: LNDC) shares gained 4.13 percent to close at $11.86 a share Monday. The stock traded between $11.28 and $11.95 on volume of 174,642 shares traded. Analysts at Lake Street have recently initiated coverage on the company with a “buy” rating and a price target of $15.00. Shares of Landec have fallen approximately 2.0 percent year-to-date.

Find out more about Landec including full access to the free equity report at:       
www.RDInvesting.com/LNDC

National Bank of Greece (NYSE: NBG) shares spiked 12.66 percent to close at $5.43 a share Monday. The stock traded between $4.93 and $5.43 on volume of 9.58 million shares traded. Analysts at Deutsche Bank have recently initiated coverage on the company with a “buy” rating. Shares of the National Bank of Greece have fallen approximately 3.0 percent year-to-date.

Find out more about National Bank of Greece including full access to the free equity report at:        
www.RDInvesting.com/NBG

PharmAthene, Inc. (NYSEMKT: PIP) shares gained 3.16 percent to close at $1.96 a share Monday. The stock traded between $1.91 and $2.05 on volume of 518,447 shares traded. Analysts at H.C. Wainwright have recently initiated coverage on the company with a “buy” rating and a price target of $4.00. Shares of PharmAthene have gained approximately 5.0 percent year-to-date.

Find out more about PharmAthene including full access to the free equity report at:     
www.RDInvesting.com/PIP

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:           
Research Driven Investing      
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *